CONTINUOUS ADMINISTRATION OF ENDOSTAR PLUS GP CHEMOTHERAPY IN LOCAL ADVANCED OR METASTATIC LUNG SQUAMOUS CELL CARCINOMA

HONG SHEN¹ , JING ZHAO¹ , SHAN-SHAN WENG¹ , XUE-FENG FANG¹ , YI-YANG ZHANG² , JIAN-JIN HUANG¹

¹ Department of Medical Oncology, 2nd Hospital of Zhejiang University School of Medicine - ² Department of Medical center, Hangzhou sanatorium of people’s Liberation Army

Introduction: In squamous cell lung cancer (SQCLC), the current first-line therapy is considered platinum-based doublet chemotherapy and the benefit is limited. Aim of our study is to compare the effect of patients with local advanced or metastatic SQCLC, in comparable groups of patients treated with systemic chemotherapy containing gemcitabine/cisplatin (GP) or GP Endostar.

Materials and methods: All patients with local advanced or metastatic SQCLC who had undergone GP continuous administration of Endostar from September 2009 to January 2014 were evaluated. The GP group was constituted by selecting patients with local advanced or metastatic SQCLC treated with GP chemotherapy during the same period.

Results: Fifty-two patients were retrospectively included in the GP group and were compared with 98 patients who had undergone continuous administration of Endostar GP and were evaluated prospectively. All characteristics were comparable. Median followup was 60 months in the GP group versus 58 months in the Endostar GP group. The response rate (RR) was 34.7% in Endostar GP group and 34.6% in the GP group. The disease control rate (DCR) was 89.7% in Endostar GP group and 80.8% in the GP group. Both the RR and DCR were not found to be significantly different with each other. Median progression free survival (PFS) was 5.56 months in the GP group versus 7.23 months in the Endostar GP group.

Discussion: The combination of continuous infusion of Endostar with chemotherapy can improve the PFS in local advanced or metastatic SQCLC patients without increasing adverse events